2Heathcote EJ . Management of primary biliary cirrhosis . The American Association for the study of liver diseases practice guidelines. Hepatology,2000,31(4): 1005-1013.
3Kaplan MM, Gershwin ME. Primary biliary cirrhosis [ J]. N Engl J Med, 2005, 353 (12): 1261 -1273.
4Kouroumalis E. Pathogenesis of PBC [ J ]. World J Gastroenterol, 2006, 12 (15) : 2320-2327.
5Amano K, Leung PS, Rieger R, et al. Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food addictive, 2 octynoic acid [ J]. J Immunol,2005, 174 (9): 5874-5883.
6Heathcote EJ, Cauch Dudek K, Walker V, et al. The Canadian multicenter double - blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis [ J ]. Hepatology,1994, 19 (5): 1149-1156.
7Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis [ M/CD]. The Cochrane Database of Systematic Revlews 2001, Issue4. Art. No. CD000551. DOI: 10. 1002/14651858. CD000551.
8Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis [J]. Gastroenterology, 2005, 128 (2): 297-303.
9Combes B, Emerson SS, Flye NL, et al. Methotrexate (MTC) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis [J]. Hepatology, 2005, 42 (5) : 1184 -1193.
10Rautiainen H, Karkkainen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three - year randomized trial [ J ]. Hepatology,2005, 41 (4): 747-752,
8Liu H,Liu Y,Wang L. Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China[J].Bmc Gastroenterology,2010.100.
9Heathcote E J. Management of primary biliary cirrhosis.The American association for the study of liver diseases practice guidelines[J].Hepatology,2000,(04):1005-1013.
